3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
49
Lung Neoplasms
12
Neoplasms
3
Adenocarcinoma
3
Carcinoma, Squamous Cell
2
ALK-positive NSCLC
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Multiple Endocrine Neoplasia Type 2a
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma
1
Hematologic Neoplasms
1
Granuloma, Plasma Cell
1
Glioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Large Cell
1
Interventions
Docetaxel
3
Carboplatin
3
motexafin gadolinium
2
figitumumab
2
cemiplimab
2
brigatinib
2
alpha-2'-deoxythioguanosine
2
Paclitaxel
2
vandetanib
1
temoporfin
1
tanespimycin
1
Vinorelbine
1
Temozolomide
1
Radiotherapy
1
Radiosurgery
1
Pemetrexed
1
Oxaliplatin
1
Gemcitabine
1
Everolimus
1
Erlotinib Hydrochloride
1
Crizotinib
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Large Cell
×
Crizotinib
×
Thoracic
×
Clear all
NCT02737501
2021-08-20
ALTA-1L
Takeda
Phase 3
Completed
275 enrolled
23 charts
1 FDA